Lumiliximab
- Generic Name
- Lumiliximab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 357613-86-6
- Unique Ingredient Identifier
- 8Z13S29R5A
- Background
Lumiliximab is a chimeric monoclonal antibody which is used as an immunosuppressive drug. It is a primatized anti-CD23 macaque/human chimeric antibody that inhibits the production of the IgE antibody, for the potential treatment of allergic conditions. Lumiliximab was developed by IDEC Pharmaceuticals, which was acquired by Biogen. Clinical trials for CLL were terminated in 2010, and for allergic asthma in 2007. Results published from the CLL clinical trial failed to meet primary endpoints.
- Indication
Investigated for use/treatment in asthma and leukemia (lymphoid).
- Associated Conditions
- -
- Associated Therapies
- -
New Agents for Targeted Treatment of Lymphoma
Advances in understanding lymphoma's molecular biology have identified potential therapeutic targets, leading to new agents like monoclonal antibodies and small-molecule inhibitors. Despite progress, drug development remains slow, with challenges in identifying 'driver' molecular defects and predictive biomarkers. The review highlights the need for focused research to accelerate the approval of promising drugs for lymphoma treatment.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath